Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B
Status:
Unknown status
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This trial is to assess the efficacy and safety of Polyethylene Glycol thymosin alpha1
(PEG-Tα1), a new long immunomodulator (Category 1.1 of Chemical Drugs) being developed from
Hansoh Pharmaceutical of China, in combination with adefovir in HBeAg-positive patients with
chronic hepatitis B.